Osiris/Genzyme Anticipate Approval Of Stem Cell Therapy Prochymal By 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
Submission for graft-versus-host disease indication begins under a rolling BLA this quarter, with final data due at mid-year and a possible six-month review for the first therapy of its kind.
You may also be interested in...
Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD
Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.
Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD
Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.
Osiris/Genzyme Put Stem Cells On The Deal Map
First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.